Neuronetics/$STIM
1D1W1MYTD1Y5YMAX
About Neuronetics
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
- Ticker
- $STIM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 658
- Headquarters
- Malvern, United States
- Website
- neurostar.com/neuronetics
Neuronetics Metrics
BasicAdvanced
$224M
-
-$0.44
1.12
-
Price and volume
Market cap
$224M
Beta
1.12
52-week high
$3.71
52-week low
$0.80
Average daily volume
2.6M
Financial strength
Current ratio
1.88
Quick ratio
1.25
Long term debt to equity
376.063
Total debt to equity
399.829
Interest coverage (TTM)
-2.52%
Profitability
EBITDA (TTM)
-19.263
Gross margin (TTM)
49.38%
Net profit margin (TTM)
-19.62%
Operating margin (TTM)
-14.48%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-10.55%
Return on equity (TTM)
-116.10%
Valuation
Price to revenue (TTM)
1.322
Price to book
12.55
Price to tangible book (TTM)
-9.07
Price to free cash flow (TTM)
-18.22
Free cash flow yield (TTM)
-5.49%
Free cash flow per share (TTM)
-0.161
Growth
Revenue change (TTM)
39.59%
Earnings per share change (TTM)
-56.37%
3-year revenue growth (CAGR)
31.73%
3-year earnings per share growth (CAGR)
-27.18%
Neuronetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.